Shanghai Henlius Biotech (HKSE:02696) EV-to-Revenue : 5.03 (As of Dec. 11, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Shanghai Henlius Biotech EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Shanghai Henlius Biotech's enterprise value is HK$15,765 Mil. Shanghai Henlius Biotech's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was HK$3,136 Mil. Therefore, Shanghai Henlius Biotech's EV-to-Revenue for today is 5.03.

The historical rank and industry rank for Shanghai Henlius Biotech's EV-to-Revenue or its related term are showing as below:

HKSE:02696' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.39 Med: 377.74 Max: 1440.61
Current: 5.03

During the past 7 years, the highest EV-to-Revenue of Shanghai Henlius Biotech was 1440.61. The lowest was 2.39. And the median was 377.74.

HKSE:02696's EV-to-Revenue is ranked better than
61.77% of 1041 companies
in the Biotechnology industry
Industry Median: 7.7 vs HKSE:02696: 5.03

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-12-11), Shanghai Henlius Biotech's stock price is HK$22.25. Shanghai Henlius Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was HK$5.77. Therefore, Shanghai Henlius Biotech's PS Ratio for today is 3.86.

Shanghai Henlius Biotech EV-to-Revenue Historical Data

The historical data trend for Shanghai Henlius Biotech's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Henlius Biotech EV-to-Revenue Chart

Shanghai Henlius Biotech Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

200.28

37.66

7.28

2.87

1.86

Shanghai Henlius Biotech Quarterly Data
	Dec17	Mar18	Jun18	Dec18	Mar19	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23	Jun24
EV-to-Revenue	Get a 7-Day Free Trial													2.87	4.41	3.38	1.86	5.13

Competitive Comparison of Shanghai Henlius Biotech's EV-to-Revenue

For the Biotechnology subindustry, Shanghai Henlius Biotech's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shanghai Henlius Biotech's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Henlius Biotech's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Shanghai Henlius Biotech's EV-to-Revenue falls into.

Shanghai Henlius Biotech EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Shanghai Henlius Biotech's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	15765.336	/	3135.798
	=	5.03

Shanghai Henlius Biotech's current Enterprise Value is HK$15,765 Mil.
Shanghai Henlius Biotech's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$3,136 Mil.

Shanghai Henlius Biotech (HKSE:02696) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Shanghai Henlius Biotech's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	22.25	/	5.769
	=	3.86

Shanghai Henlius Biotech's share price for today is HK$22.25.
Shanghai Henlius Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$5.77.

Shanghai Henlius Biotech EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Shanghai Henlius Biotech's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Henlius Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Henlius Biotech Inc (HKSE:02696) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

B8 Building, No. 188 Yizhou Road, 11th Floor, Xuhui District, Shanghai, CHN, 200233

Website

https://www.henlius.com

Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and innovative biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China and Overseas. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.

Executives

Qatar Investment Authority	2201 Interest of corporation controlled by you
Fosun Industrial Co., Limited	2101 Beneficial owner
Shanghai Fosun Pharmaceutical (group) Co., Ltd.	2201 Interest of corporation controlled by you
Fosun Holdings Limited	2201 Interest of corporation controlled by you
Fosun International Holdings Ltd.	2201 Interest of corporation controlled by you
Fosun International Limited	2201 Interest of corporation controlled by you
Guo Guangchang	2201 Interest of corporation controlled by you
Shanghai Fosun High Technology (group) Co., Ltd.	2201 Interest of corporation controlled by you
Liu Scott Shi-kau	2201 Interest of corporation controlled by you
Jiang Wei-dong	2201 Interest of corporation controlled by you
Henlius Biopharmaceuticals, Inc.	2101 Beneficial owner

Shanghai Henlius Biotech Headlines

No Headlines